These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 9364835)

  • 21. Fungal nail infections.
    Crawford F; Ferrari J
    Clin Evid; 2005 Dec; (14):2036-43. PubMed ID: 16620479
    [No Abstract]   [Full Text] [Related]  

  • 22. Fungal toenail infections.
    Crawford F; Ferrari J
    Clin Evid; 2006 Jun; (15):2212-20. PubMed ID: 16973086
    [No Abstract]   [Full Text] [Related]  

  • 23. Terbinafine: a review of its use in onychomycosis in adults.
    Darkes MJ; Scott LJ; Goa KL
    Am J Clin Dermatol; 2003; 4(1):39-65. PubMed ID: 12477372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Onychomycosis: a new emerging infectious disease in childhood population and adolescents. Report on treatment experience with terbinafine and itraconazole in 36 patients.
    Ginter-Hanselmayer G; Weger W; Smolle J
    J Eur Acad Dermatol Venereol; 2008 Apr; 22(4):470-5. PubMed ID: 18194238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence.
    Gupta AK; Ryder JE; Lynch LE; Tavakkol A
    J Drugs Dermatol; 2005; 4(3):302-8. PubMed ID: 15898285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Itraconazole and terbinafine in perspective. From petri dish to patient.
    De Doncker P; Gupta AK
    Postgrad Med; 1999 Jul; Spec No():6-11. PubMed ID: 10492660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Newer systemic antifungal drugs for the treatment of onychomycosis.
    Chiritescu MM; Chiritescu ME; Scher RK
    Clin Podiatr Med Surg; 1996 Oct; 13(4):741-58. PubMed ID: 8902341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral therapeutic agents in fungal nail disease.
    Roberts DT
    J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S78-81. PubMed ID: 8077514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating onychomycosis.
    Rodgers P; Bassler M
    Am Fam Physician; 2001 Feb; 63(4):663-72, 677-8. PubMed ID: 11237081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A questionnaire study on the management of onychomycosis: a Canadian perspective.
    Gupta AK; Shear NH
    Int J Dermatol; 1998 Jun; 37(6):457-60. PubMed ID: 9646138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model.
    Marchetti A; Piech CT; McGhan WF; Neugut AI; Smith BT
    Clin Ther; 1996; 18(4):757-77; discussion 702. PubMed ID: 8879902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toenail onychomycosis: current and future treatment options.
    Finch JJ; Warshaw EM
    Dermatol Ther; 2007; 20(1):31-46. PubMed ID: 17403258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An independent comparison of terbinafine and itraconazole in the treatment of toenail onychomycosis.
    Cohen AD; Medvesovsky E; Shalev R; Biton A; Chetov T; Naimer S; Shai A; Vardy DA
    J Dermatolog Treat; 2003 Dec; 14(4):237-42. PubMed ID: 14660272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New antifungal agents.
    Lesher JL
    Dermatol Clin; 1992 Oct; 10(4):799-805. PubMed ID: 1327600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral treatment options for onychomycosis.
    Joseph WS
    J Am Podiatr Med Assoc; 1997 Nov; 87(11):520-31. PubMed ID: 9397657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus.
    Gupta AK; Gover MD; Lynde CW
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1188-93. PubMed ID: 17062029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine].
    Bergman W; Rutten FF
    Ned Tijdschr Geneeskd; 1994 Nov; 138(47):2346-50. PubMed ID: 7969635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.
    Gupta AK; Shear NH
    Drug Saf; 2000 Jan; 22(1):33-52. PubMed ID: 10647975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
    Rosen T; Stein Gold LF
    Semin Cutan Med Surg; 2016 Mar; 35(3 Suppl 3):S51-5. PubMed ID: 27074700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective treatment for dermatophytoses of the foot: effect on restoration of depressed cell-mediated immunity.
    Schmid-Wendtner MH; Korting HC
    J Eur Acad Dermatol Venereol; 2007 Sep; 21(8):1013-8. PubMed ID: 17714119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.